Skip Navigation LinksBrain

​​​​​​​Brain Trials


Cancer Control/Prevention

A221101​​: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme​

​L​ow-Grade Glioma

Anaplastic Glio​ma (Grade III)

N0577: Phase III Intergroup Study of Temozolomide Alone vs. Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

 

Newly Diagnosed Glioblastoma Multiforme​ (Grade IV)

A071102:  A Phase II/III Randomized Trial Of ​Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation​​​​

ICT-107-301:  Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III Randomized Double-blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

RTOG 3508 (M13-813)​: A Randomized, Placebo Controlled Phase 2b/3 STudy of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Wpidermal Growth Factor Receptor (EGFR) Amplification (Intellence 1)

​​​Recurrent Glioblastoma Multiforme


Metastatic Brain

​R1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer


​A071401:  Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations